Rezultati

eNauka >  Rezultati >  PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Naziv: PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Autori: Chia Stephen K. L.; Miguel Martin; Holmes Frankie A.; Ejlertsen Bent; Delaloge Suzette; Moy Beverly; Iwata Hiroji; von Minckwitz Gunter; Mansi Janine; Barrios Carlos H;
Gnant Michael; Tomašević Zorica; Denduluri Neelima; Šeparović Robert; Kim Sung-Bae; Jakobsen Erik Hugger; Harvey Vernon; Robert Nicholas; Smith II John; Harker Graydon; Zhang Bo; Eli Lisa D; Ye Yining; Lalani Alshad S; Buyse Marc; Chan Arlene;
Godina: 2019
Publikacija: Breast Cancer Res 21(1) 39
ISSN: 1465-542X Breast Cancer Research Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 21 br. 1
DOI: 10.1186/s13058-019-1115-2
WoS-ID: 000461337400001
Scopus-ID: 2-s2.0-85062890379
PMID: 30867034
PMCID: PMC6417207
URI: https://zenodo.org/record/4474850
https://enauka.gov.rs/handle/123456789/597531
Projekat: url:https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1115-2
M-kategorija: 
21aM21a - Vodeći međunarodni časopis kategorije M21a

21
SCOPUSTM
14
PubMed CentralTM
12
OpenCitations
21
WEB OF SCIENCETM
Alt metrika
Dimensions
Unpaywall

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.